

ERN GENTURIS ONLINE CONFERENCE 2025

WHAT'S NEW IN HEREDITARY CANCER?

20 MARCH 2025

09:00-17:00 CET

MORNING SESSIONS:

9:00 - 11:30 CET

NEW GUIDELINES AND
PATIENT'S CONCERNS

AFTERNOON SESSIONS:

12:40 - 17:00 CET

RESEARCH,
NEW TREATMENTS,
THE FUTURE OF HEREDITARY
CANCER

What's new in hereditary cancer?

Thursday 20 March 2025

The conference flyer, including QR-codes linking to the ERN GENTURIS online conference 2025 webpage, is available [here](#).

Free registration

Morning sessions on **new guidelines** and **patient's concerns** – [Register here](#)

Afternoon sessions on **research, new treatments** and **the future of hereditary cancer** – [Register here](#)

Programme

The conference will feature updates on the ERN GENTURIS new guidelines, patient's concerns, research, new treatments and the future of hereditary cancer.

09:00 - 10:15 CET : NEW GUIDELINES

Moderator: Verena Steinke-Lange

Time	Speaker	Title
09:00 - 09:05	Mateja Krajc	Opening of the conference
09:05 - 09:25	Chrystelle Colas	Constitutional Mismatch Repair Deficiency (CMMRD)
09:25 - 09:45	Marianne Geilswijk	Birt-Hogg-Dubé syndrome
09:45 - 10:05	Rianne Oostenbrink	Neurofibromatosis type 1
10:05 - 10:15	All session speakers	Discussion

10:15 - 10:20 CET : SHORT BREAK

10:20 - 11:30 CET : PATIENT'S CONCERNS

Moderator: Claas Röhl

Time	Speaker	Title
10:20 - 10:40	Anke Oerlemans	Family planning, Newborn screening /Ethical issues
10:40 - 11:00	Rolf Sijmons	ERN Registry (the latest progression and patient portal
11:00 - 11:20	Matt Bolz-Johnson	Mental Health (how do rare conditions impact family and social relationships
11:20 - 11:30	All session speakers	Discussion

11:30 - 12:40 CET : LUNCH BREAK

12:40 - 14:30 CET : RESEARCH

Moderator: Karin Wadt

Time	Speaker	Title
12:40 - 13:00	Richarda de Voer	Solve-RD - solving the unsolved rare diseases
13:00 - 13:20	Carla Oliveira	PREVENTABLE project: sustainable care for rare tumour risk syndromes
13:20 - 13:40	Jolanda de Vries	Harnessing the Immune System to Prevent Lynch Syndrome-Associated Cancers: Promising Results with Dendritic Cell Vaccination Targeting Frameshift Mutations.
13:40 - 14:00	Lise Borgwardt	What's new in imaging: total body PET/CT and its potential role for cancer predisposition surveillance
14:00 - 14:20	Verena Steinke-Lange	Evolution of liquid biopsy methods for colorectal cancer screening
14:20 - 14:30	All session speakers	Discussion

14:30 - 14:35 CET : SHORT BREAK

14:35 - 16:05 CET : NEW TREATMENTS

Moderator: Svetlana Bajalica Lagercrantz

Time	Speaker	Title
14:35 - 14:55	Marjolijn Ligtenberg	Molecular cancer profiles open the way to personalized treatment options for patients with a <i>BRCA1/2</i> pathogenic variant
14:55 - 15:15	Judith Balmaña	PARPi – indications and mainstreaming
15:15 - 15:35	Antonella Cacchione	NF1 and new treatments
15:35 - 15:55	Eamonn Maher	VHL and inherited renal cancer syndromes and new treatments
15:55 - 16:05	All session speakers	Discussion

16:05 - 16:10 CET : SHORT BREAK

16:10 - 17:00 CET : THE FUTURE OF HEREDITARY CANCER

Moderator: Tiina Kahre

Time	Speaker	Title
16:10 - 16:30	Svetlana Bajalica Lagercrantz	Future perspectives in the era of mainstream testing
16:30 - 16:40	All session speakers	Discussion
16:40 - 17:00	Nicoline Hoogerbrugge	The past and the future of ERN GENTURS

17:00 CET : END OF CONFERENCE

Scientific and organising committee:

Mateja Krajc (Institute of Oncology Ljubljana, Slovenia)

Svetlana Bajalica Lagercrantz (Karolinska University Hospital, Sweden)

Verena Steinke-Lange (Medizinisch Genetisches Zentrum, Germany)

Karin Wadt (Rigshospitalet Copenhagen, Denmark)

Tiina Kahre (Tartu University Hospital, Estonia)

Claas Röhl (NF Kinder, Austria)

Jurriaan Hölzenspies (Radboud university medical center, Nijmegen)